This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

The content of this website has been produced in line with the BESPONSA®▼ (inotuzumab ozogamicin) Summary of Product Characteristics for Great Britain and is intended for Healthcare Professionals based in Great Britain. BESPONSA▼ Prescribing Information for Great Britain click here. BESPONSA▼ Prescribing Information for Northern Ireland click here. Adverse event reporting information can be found at the bottom of the page.

Key data from the INO-VATE study video

Speaker: Dr. Anna Castleton

Duration: 05:22

In this video, Dr Castleton discusses the INO-VATE study with particular reference to the following:

  • BESPONSA mechanism of action
  • Phase III INO-VATE study1: BESPONSA vs. standard chemotherapy
    • Study population and eligibility
    • Study endpoints: Remission Rates and Overall Survival
    • Adverse Event profile
    • Management of hepatic toxicity and veno-occlusive disease and risk factors
    • Bridging to transplantation
    • Number of cycles required to achieve remission rates

  • BESPONSA mechanism of action
  • Phase III INO-VATE study1: BESPONSA vs. standard chemotherapy​​​​​​​
    • Study population and eligibility
    • Study endpoints: Remission Rates and Overall Survival
    • Adverse Event profile
    • Management of hepatic toxicity and veno-occlusive disease and risk factors
    • Bridging to transplantation
    • Number of cycles required to achieve remission rates
Dr. Anna Castleton graduated from Newcastle University medical school in 2001. She undertook her general medical training in Newcastle and London, and specialist haematology training within the North-West London Deanery. Dr Castleton was awarded a clinical research training fellowship with the LLR (Bloodwise) to undertake a period of PhD research at University College London. She moved to Manchester in 2016 to take up a consultant post in haemato-oncology at The Christie Hospital NHS Foundation Trust. Dr Castleton has expertise in a range of haematological malignancies with a specialist interest in acute lymphoblastic leukaemia (ALL) and Teenage and Young Adult (TYA) haematology. She is a member of the UK National Cancer Research Institute adult ALL subgroup.

Explore more

Developments in Leukaemia Care

Watch Professor David Marks discuss targeted therapies and the INO-VATE study, including 3 year follow up and impact of allogeneic bone marrow transplantation on survival

Learn More

Management of Refractory/Relapsed ALL

Hear Professor David Marks discuss the INO-VATE study including MRD negativity, long term survival and reducing risks of veno-occlusive disease

Learn More
MRD, minimal residual disease; SmPC, Summary of product characteristics
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
Reference:
  1. ​​​​​​​Kantarjian HM, et al. New Engl J Med. 2016;375:740-53.
PP-INO-GBR-0514. August 2021

Register to receive tailored marketing information from Pfizer by email

Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.

PP-PFE-GBR-2809. March 2021

Sign up now

Fast Facts

Download the Fast Facts Guide holding the key information for BESPONSA including mode of action, INO-VATE study design, INO-VATE results; efficacy and safety profile. Summary of Product Characteristics (SmPC) should be consulted for full guidance.

Download here

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No